Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab Plus Stereotactic Body Radiotherapy (SBRT) in II and III Line of Patients With Metastatic Renal Cell Carcinoma (mRCC)

Trial Profile

Nivolumab Plus Stereotactic Body Radiotherapy (SBRT) in II and III Line of Patients With Metastatic Renal Cell Carcinoma (mRCC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms NIVES
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Aug 2018 Planned primary completion date changed from 14 Jul 2018 to 14 Jul 2019.
    • 05 Jun 2018 According to the results presented at the 54th Annual Meeting of the American Society of Clinical Oncology, 20 of the planned 68 patients were enrolled from July 2017 to January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top